

BIOSIMILARS AND ACCESS TO BIOLOGIC THERAPIES IN IMMUNE-MEDIATED DISEASES



OBJECTIVE

Assess the **impact** of the commercialization of **biosimilar medicines** on the **access to biological therapy (BT)** for the treatment of **immune-mediated inflammatory diseases (IMID)**. With this purpose an observational, retrospective and longitudinal, and multicenter **study** is carried out in **15 hospitals in 9 Autonomous Communities**.





INCLUSION CRITERIA

- **IMID diagnosis:** rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease and ulcerative colitis.
- **BT naive patient with:** infliximab, etanercept or adalimumab originator or biosimilar.
- **BT start date:** minimum 1 year prior to the marketing of the biosimilar medicine.



RESULTS



CONCLUSION

The **market launch of biosimilars** has **reduced** the **patient waiting time** to receive a BT by **1.6 years (19 months)**.

